Reviva Pharmaceuticals Files 8-K Report

TL;DR

Reviva Pharma dropped an 8-K, check it for the latest deets.

AI Summary

On July 9, 2024, Reviva Pharmaceuticals Holdings, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. The company, formerly Tenzing Acquisition Corp., is incorporated in Delaware and based in Cupertino, CA.

Why It Matters

This 8-K filing provides updated information and disclosures for Reviva Pharmaceuticals Holdings, Inc., which is important for investors to stay informed about the company's status and any material events.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.

Key Players & Entities

• REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Registrant
• Tenzing Acquisition Corp. (company) — Former company name
• July 9, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 10080 N Wolfe Road , Suite SW3-200 (address) — Business and mailing address

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share RVPH Nasdaq Capital Marke

Filing Documents

• rvph20240709_8k.htm (8-K) — 32KB
• ex_696230.htm (EX-99.1) — 14KB
• 0001437749-24-022354.txt ( ) — 200KB
• rvph-20240709.xsd (EX-101.SCH) — 4KB
• rvph-20240709_def.xml (EX-101.DEF) — 14KB
• rvph-20240709_lab.xml (EX-101.LAB) — 18KB
• rvph-20240709_pre.xml (EX-101.PRE) — 14KB
• rvph20240709_8k_htm.xml (XML) — 5KB

01

Item 7.01. Regulation FD Disclosure. On July 9, 2024, Reviva Pharmaceuticals Holdings, Inc. (the "Company") issued a press release announcing the grant of a European patent covering use of brilaroxazine for the treatment of pulmonary hypertension. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01

Item 8.01. Other Events. On July 9, 2024, the Company announced that European Patent EP3244896 has been granted by the European Patent Office (EPO) covering use of brilaroxazine for the treatment of pulmonary hypertension (PH), adding to the Company's existing patent protection in key markets around the world including the United States, China and Japan. The European patent covers brilaroxazine use for treating PH and pulmonary arterial hypertension (PAH) in any patients and treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD). Brilaroxazine has received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of PAH.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) The following Exhibit 99.1 is furnished with this report: Exhibit No. Description 99.1 Press Release issued by Reviva Pharmaceuticals Holdings, Inc., dated July 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVIVA PHARMACEUTICALS HOLDINGS, INC. Date: July 9, 2024 By: /s/ Narayan Prabhu Name: Narayan Prabhu Title: Chief Financial Officer